💰 Financial Performance

Revenue Growth by Segment

Innovea division grew 57% YoY to INR 33 Cr in FY25. Thervea division grew 105% YoY to INR 14 Cr in FY25. Total H1FY26 revenue was INR 25.3 Cr, an 8.6% decrease from INR 27.7 Cr in H1FY25 due to strategic credit tightening and seasonal factors.

Geographic Revenue Split

The company operates a pan-India distribution network across major metros and Tier 1/2 cities including Mumbai, Delhi, Bangalore, Chennai, Hyderabad, Kolkata, Patna, Chandigarh, Pune, Indore, and Ahmedabad. Specific percentage split per region is not disclosed.

Profitability Margins

Gross margins remained stable at 54.8% in H1FY26 compared to 57.4% in FY25. Owned brands command higher gross margins of approximately 70% compared to 60% for imported brands. PAT margin declined to -3.1% in H1FY26 from 1.7% in H1FY25.

EBITDA Margin

Operating EBITDA margin collapsed to 0.3% (INR 0.07 Cr) in H1FY26 from 5.4% (INR 1.5 Cr) in H1FY25, a 510 bps decline. This was driven by one-time strategic investments, higher employee costs for new divisions, and lower revenue realization during credit term tightening.

Capital Expenditure

The company follows an asset-light 'Zero Capex' model for distribution. IPO proceeds of INR 27 Cr (June 2025) are primarily being deployed for working capital requirements rather than heavy fixed asset expansion.

Credit Rating & Borrowing

Short-term borrowings stood at INR 17.1 Cr in H1FY26, down from INR 22.7 Cr in FY25. Finance costs for H1FY26 were INR 1.0 Cr. Specific credit ratings and interest rate percentages were not disclosed.

⚙️ Operational Drivers

Raw Materials

Medical injectable aesthetics, skincare formulations, exosome regenerative products, and aesthetic devices. Specific chemical/raw material cost percentages are not disclosed as the company primarily operates in brand management and distribution.

Import Sources

Italy (specifically for the VM tie-up for Exovia division) and other international markets for in-licensed aesthetic brands.

Key Suppliers

VM (Italy) for regenerative products; other international aesthetic manufacturers for the in-licensed portfolio.

Capacity Expansion

Not applicable as the company is asset-light; however, the sales force has expanded to 100+ personnel to support new divisions like Exovia.

Raw Material Costs

COGS as a percentage of sales was 43% in FY25 and 45% in H1FY26. The strategy involves shifting from imported to owned brands to reduce COGS and forex volatility.

Manufacturing Efficiency

Per-person productivity was approximately INR 0.05 Cr (5 Lakhs) last year. The company expects operational leverage to improve as new division staff reach full productivity.

Logistics & Distribution

Professional logistics handling is used to cut product damage and pilferage. Distribution is managed through a dedicated AR team to improve collections.

📈 Strategic Growth

Expected Growth Rate

30%

Growth Strategy

Achieving 30% CAGR through divisionalization (Innovea, Thervea, Rejuvea, Techvea), launching the new 'Exovia' division for high-end exosome products, shifting revenue mix toward 70% margin owned brands (currently 38% of revenue), and expanding the doctor reach beyond the current 14,000 professionals.

Products & Services

Medical injectable aesthetics, skincare products, hair care treatments, regenerative exosome products, and aesthetic medical devices.

Brand Portfolio

TUBELiTE (skincare), Tubelight GFC (hair care), DRS 1512, Exovia (regenerative), Innovea, Thervea, Rejuvea, Techvea.

New Products/Services

Exovia division launching high-end regenerative exosome products from VM Italy; Tubelight GFC for hair care; DRS 1512 currently in clinical pilot phase.

Market Expansion

Targeting deeper penetration in Tier 1 and Tier 2 towns with a 100+ member sales force and aiming for a Main Board listing to increase corporate visibility.

Market Share & Ranking

The company claims to be the only aesthetic company in India with such a broad portfolio; currently outpacing the industry growth of 9-10% by growing at 30%+.

Strategic Alliances

Tie-up with VM (Italy) for the Exovia division to bring high-end regenerative products to the Indian metro markets.

🌍 External Factors

Industry Trends

The aesthetic market is growing at 9-10% CAGR. Trends are shifting toward regenerative medicine (exosomes) and non-invasive injectable aesthetics where Aakaar is positioning its new Exovia division.

Competitive Landscape

Competes with both Indian and multinational aesthetic companies; positions itself as having the broadest portfolio in the Indian market.

Competitive Moat

Moat built on a broad product portfolio, a network of 14,000 doctors, and an asset-light distribution model. The shift to owned brands (38% of revenue) creates higher switching costs and brand loyalty compared to pure trading.

Macro Economic Sensitivity

Sensitive to consumer discretionary spending on aesthetic procedures; however, the high share of recurring aesthetic products (43% of COGS) provides revenue consistency.

Consumer Behavior

Increasing demand for hair care (Tubelight GFC) and high-end metro-based regenerative treatments.

Geopolitical Risks

Historical impacts noted from wars (Ukraine, Israel) affecting supply chains; current strategy focuses on 'Tech in India' to reduce global dependency.

⚖️ Regulatory & Governance

Industry Regulations

Subject to CDSCO/medical device regulations; recently underwent regulatory transitions for packaging and licensing following the conversion from a Private Limited to a Public Limited company.

Environmental Compliance

Not disclosed as a significant factor for this business type.

Taxation Policy Impact

Effective tax expense was INR 2.1 Cr in FY25; H1FY26 saw a tax credit of INR 0.2 Cr due to reported losses.

Legal Contingencies

No specific pending court cases or values were disclosed in the provided documents.

⚠️ Risk Analysis

Key Uncertainties

Success of the credit tightening policy (targeting <100 receivable days) and the ability to maintain 30% CAGR while transitioning to a more stable cash-flow model.

Geographic Concentration Risk

Concentrated in India with a focus on major metros for high-end products; 100+ sales staff are primarily located in metros and Tier 1 cities.

Third Party Dependencies

Dependency on VM (Italy) for the new Exovia division's product pipeline and PISPL for nationwide logistics.

Technology Obsolescence Risk

Risk in the aesthetic device segment; mitigated by working 3 years ahead on product visibility and regulatory approvals.

Credit & Counterparty Risk

Receivable days ballooned to 131 days in FY25, prompting a strategic shift to stricter credit controls to ensure long-term cash flow stability.